The FAOs 2017 report discussed three principal reasons for the recent increase in hunger: climate, conflict, and economic slowdowns. The 2018 edition focused on extreme weather as a primary driver of the increase in hunger, finding rising rates to be especially severe in countries where agricultural systems were most sensitive to extreme weather variations. The 2019 SOFI report found a strong correlation between increases in hunger and countries that had suffered an economic slowdown. The 2020 edition instead looked at the prospects of achieving the hunger related Sustainable Development Goal (SDG). It warned that if nothing is done to counter the adverse trends of the past six years, the number of people suffering from chronic hunger is on track to rise by over 150 million by 2030. The 2021 report reported a sharp jump in hunger caused by the COVID-19 pandemic. Many thousands of organizations are engaged in the field of hunger relief, operating at local, national, regional, or international levels. Some of these organizations are dedicated to hunger relief, while others may work in several different fields. The organizations range from multilateral institutions to national governments, to small local initiatives such as independent soup kitchens. Many participate in umbrella networks that connect thousands of different hunger relief organizations. At the global level, much of the worlds hunger relief efforts are coordinated by the UN and geared towards achieving SDG 2 of Zero Hunger by 2030.
Pharmacology
Ropinirole acts as a D2, D3, and D4 dopamine receptor agonist with highest affinity for D3, which are mostly found in the limbic areas. It is weakly active at the 5-HT2, and α2 receptors and is said to have virtually no affinity for the 5-HT1, GABA, mAChRs, α1, and β-adrenoreceptors.Ropinirole is metabolized primarily by cytochrome P450 CYP1A2 to form two metabolites; SK&F-104557 and SK&F-89124, both of which are renally excreted, and at doses higher than clinical, is also metabolized by CYP3A4. At doses greater than 24 mg, CYP2D6 may be inhibited, although this has been tested only in vitro. Society and culture
It is manufactured by GlaxoSmithKline (GSK), Mylan Pharmaceuticals, Cipla, Dr. Reddys Laboratories and Sun Pharmaceutical. The discovery of the drugs utility in RLS has been used as an example of successful drug repurposing. Lawsuits
In November 2012, GlaxoSmithKline was ordered by a Rennes appeals court to pay Frenchman Didier Jambart 197,000 euros ($255,824); Jambart had taken ropinirole from 2003 to 2010 and exhibited risky hypersexual behavior and gambled excessively until stopping the medication. References
External links
"Ropinirole". Drug Information Portal. U.S. National Library of Medicine. "Ropinirole hydrochloride". Drug Information Portal. U.S. National Library of Medicine.